1. WHO, Treatment of Tuberculosis. Guidelines for National Programmes, WHO, WHO/TB/97, World Health Organization, Geneva (1997) 220.
2. Isoniazid;Brewer,1977
3. Impaired bioavailability of rifampicin from fixed dose combination formulations with isoniazid;Shishoo;Indian J. Pharm. Sci.,2001
4. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat;Singh;Int. J. Tuberc. Lung Dis.,2003
5. Biopharmaceutical aspects of multiparticulates;Kramer,1994